EPIX

Insider Trades

Name	Value	Action	Price	Current Price
Bvf Partners L P/il10 Percent Owner $14879 shares SellAug 5, 2025 $1.88 --
Bvf Partners L P/il10 Percent Owner $12466 shares SellAug 5, 2025 $1.88 --
Bvf Partners L P/il10 Percent Owner $2111 shares SellAug 5, 2025 $1.88 --
Biotech Growth N V10 Percent Owner $3.1M2M shares SellNov 1, 2024 $1.53 --
Biotech Growth N V10 Percent Owner $3.1M2M shares SellNov 1, 2024 $1.53 --
Biotech Growth N V10 Percent Owner $3.1M2M shares SellNov 1, 2024 $1.53 --

Trade EPIX

About ESSA Pharma Inc.

ESSA Pharma Inc. (EPIX) functions as a clinical-stage pharmaceutical firm, concentrating its efforts on developing innovative and exclusive therapies designed to combat prostate cancer. The company's primary drug candidate is EPI-7386, an oral treatment presently undergoing Phase I clinical trials. This investigational compound is intended for individuals suffering from metastatic castration-resistant prostate cancer. Furthermore, ESSA Pharma has established collaborative partnerships with organizations including Caris Life Sciences, Inc., Bayer Consumer Care AG, Janssen Research & Development, LLC, and Astellas Pharma Inc. Founded in 2009, the company's corporate offices are located in Vancouver, Canada.

CEO: David Ross Parkinson
IPO Date: Mar 13, 2015

Market Data

Volume: 5.9M

Valuation

Valuation snapshot is not available yet.

Financials

Financial statement snapshot is not available yet.

Events

EarningsMay 6